CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells

Autor: Daniela Wesch, Matthias Peipp, Andreas Humpe, J.G.J. van de Winkel, P. W. Parren, Dieter Kabelitz, Anja Muskulus, Renate Burger, Christian Kellner, Sebastian Lutz, Martin Gramatzki, Hans-Heinrich Oberg

Publikováno v: Peipp, M, Wesch, D, Oberg, H H, Lutz, S, Muskulus, A, van de Winkel, J G J, Parren, P W H I, Burger, R, Humpe, A, Kabelitz, D, Gramatzki, M & Kellner, C 2017, ' CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells ', Scandinavian Journal of Immunology, vol. 86, no. 4, pp. 196-206 . https://doi.org/10.1111/sji.12581

Human γδ T cells are innate-like T cells which are able to kill a broad range of tumor cells and thus may have potential for cancer immunotherapy. The activating receptor natural killer group 2 member D (NKG2D) plays a key role in regulating immune

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::446e5c0ed34b1f93fde1e38c1796209d
https://pubmed.ncbi.nlm.nih.gov/28708284

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

Autor: Martino Introna, Paul W. H. I. Parren, Fabio Da Roit, Alessandro Rambaldi, Ronald P. Taylor, Giuseppe Gritti, Josée Golay, Frank J. Beurskens, Esther C.W. Breij, Patrick J. Engelberts

Publikováno v: Da Roit, F, Engelberts, P J, Taylor, R P, Breij, E C, Gritti, G, Rambaldi, A, Introna, M, Parren, P W, Beurskens, F J & Golay, J 2015, ' Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy ', Haematologica, vol. 100, no. 1, pp. 77-86 . https://doi.org/10.3324/haematol.2014.107011

The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-δ inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combinati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb00af48e71c6ed89103d123792d3918
https://doi.org/10.3324/haematol.2014.107011

Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells

Autor: Paul W. H. I. Parren, Marleen Voorhorst, Patrick J. Engelberts, Tom Vink, Frank J. Beurskens, Thomas Valerius, Wendy J.M. Mackus, Joost M. Bakker, Stefanie Derer, Tom van Meerten, Esther C.W. Breij, Janine Schuurman, Jan G. J. van de Winkel

Publikováno v: Engelberts, P J, Voorhorst, M, Schuurman, J, Van Meerten, T, Bakker, J M, Vink, T, Mackus, W J M, Breij, E C W, Derer, S, Valerius, T, van de Winkel, J G J, Parren, P W H I & Beurskens, F J 2016, ' Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells ', Journal of Immunology, vol. 197, no. 12, pp. 4829-4837 . https://doi.org/10.4049/jimmunol.1600811
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS

Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20+ B cells by binding of C1 to hexamerized Fc domains. Unexpectedly, we found that type I CD20 Ab F(ab')2 fragments,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d9197ec28f899d5e6a016465f31efa
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Autor: Finckh, A, Ciurea, A, Brulhart, L, Möller, B, Walker, U A, Courvoisier, D, Kyburz, D, Dudler, J, Gabay, C, Arthritis, on the behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid

Publikováno v: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 69, No 2 (2010) pp. 387-393
Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 387-393

Background:Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class of drugs, such as rituximab (RTX). It remains unclear in which clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f28974e832631a8607224a893fc89a
http://europepmc.org/articles/PMC2800201

Biodegradable Nanoparticles for Direct or Two-Step Tumor Immunotargeting

Autor: Leila Nobs, Franz Buchegger, Robert Gurny, Eric Allémann

Publikováno v: Bioconjugate Chemistry, Vol. 17, No 1 (2006) pp. 139-145

In this study, selective cancer cell targeting of biodegradable poly(lactic acid) (PLA) nanoparticles (NPs) has been investigated in vitro. SKOV-3 (HER2 positive) ovarian cancer and Daudi (CD20 positive) lymphoma cell targeting was mediated by anti-H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f36833eb836328ce69fa6d82ab827e
https://doi.org/10.1021/bc050137k